$286.31 Million in Sales Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter

Share on StockTwits

Equities analysts predict that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will report $286.31 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Ionis Pharmaceuticals’ earnings, with estimates ranging from $230.30 million to $332.40 million. Ionis Pharmaceuticals posted sales of $144.42 million during the same quarter last year, which suggests a positive year-over-year growth rate of 98.2%. The company is scheduled to announce its next earnings report on Friday, May 3rd.

According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year sales of $760.52 million for the current year, with estimates ranging from $727.87 million to $822.00 million. For the next financial year, analysts anticipate that the firm will report sales of $912.73 million, with estimates ranging from $595.60 million to $1.74 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Wednesday, February 27th. The company reported $2.21 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.01 by $2.20. The business had revenue of $192.00 million during the quarter, compared to the consensus estimate of $159.59 million. Ionis Pharmaceuticals had a net margin of 45.64% and a return on equity of 41.89%. The business’s revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.03) EPS.

A number of equities analysts recently weighed in on the stock. ValuEngine raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, March 15th. Piper Jaffray Companies set a $75.00 price objective on shares of Ionis Pharmaceuticals and gave the stock a “neutral” rating in a research report on Friday, March 22nd. Zacks Investment Research cut shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. Morgan Stanley set a $71.00 price objective on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a research report on Friday, March 1st. Finally, BMO Capital Markets increased their price objective on shares of Ionis Pharmaceuticals from $70.00 to $82.00 and gave the stock an “outperform” rating in a research report on Thursday, February 28th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. Ionis Pharmaceuticals presently has an average rating of “Hold” and an average price target of $66.33.

In other Ionis Pharmaceuticals news, SVP C Frank Bennett sold 9,013 shares of the firm’s stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $58.29, for a total value of $525,367.77. Following the completion of the transaction, the senior vice president now owns 33,541 shares of the company’s stock, valued at approximately $1,955,104.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Patrick R. O’neil sold 19,600 shares of the firm’s stock in a transaction that occurred on Tuesday, February 5th. The shares were sold at an average price of $59.25, for a total transaction of $1,161,300.00. Following the completion of the transaction, the senior vice president now directly owns 23,673 shares of the company’s stock, valued at approximately $1,402,625.25. The disclosure for this sale can be found here. Insiders sold a total of 339,205 shares of company stock valued at $24,034,607 in the last three months. 2.44% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the business. Huntington National Bank boosted its position in Ionis Pharmaceuticals by 159.3% in the 4th quarter. Huntington National Bank now owns 638 shares of the company’s stock valued at $34,000 after buying an additional 392 shares during the period. Essex Savings Bank purchased a new position in Ionis Pharmaceuticals in the 4th quarter valued at approximately $39,000. Laurel Wealth Advisors LLC purchased a new position in Ionis Pharmaceuticals in the 4th quarter valued at approximately $43,000. Daiwa Securities Group Inc. boosted its position in Ionis Pharmaceuticals by 29.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 890 shares of the company’s stock valued at $48,000 after buying an additional 200 shares during the period. Finally, Portfolio Solutions LLC purchased a new position in Ionis Pharmaceuticals in the 4th quarter valued at approximately $54,000. 85.05% of the stock is owned by institutional investors.

Shares of NASDAQ:IONS traded down $1.86 during mid-day trading on Thursday, reaching $83.76. 799,498 shares of the company were exchanged, compared to its average volume of 1,032,840. The company has a debt-to-equity ratio of 0.53, a quick ratio of 7.85 and a current ratio of 7.88. The stock has a market capitalization of $11.85 billion, a P/E ratio of 28.30 and a beta of 2.42. Ionis Pharmaceuticals has a 1 year low of $39.07 and a 1 year high of $86.58.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Further Reading: Do investors pay a separate front-end load every time they buy additional shares?

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Flushing Financial  Raised to Hold at BidaskClub
Flushing Financial Raised to Hold at BidaskClub
The Latest: Renovations firm says Safety measures followed
The Latest: Renovations firm says Safety measures followed
ValuEngine Lowers Flexsteel Industries  to Sell
ValuEngine Lowers Flexsteel Industries to Sell
Hawaiian  Raised to “Hold” at BidaskClub
Hawaiian Raised to “Hold” at BidaskClub
SunPower  Lowered to “Hold” at ValuEngine
SunPower Lowered to “Hold” at ValuEngine
Critical Contrast: INDIVIOR PLC/S  and Its Rivals
Critical Contrast: INDIVIOR PLC/S and Its Rivals


 
© 2006-2019 Zolmax.